CSIMarket
 
Inhibrx Inc   (INBX)
Other Ticker:  
 
 
Price: $34.9400 $-0.06 -0.171%
Day's High: $35.22 Week Perf: -0.85 %
Day's Low: $ 34.90 30 Day Perf: -8.03 %
Volume (M): 540 52 Wk High: $ 39.79
Volume (M$): $ 18,857 52 Wk Avg: $24.94
Open: $35.00 52 Wk Low: $14.30



 Market Capitalization (Millions $) 1,647
 Shares Outstanding (Millions) 47
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -241
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 5

Inhibrx Inc
Inhibrx Inc is a biopharmaceutical company that specializes in the development of innovative antibody therapeutics. The company focuses on creating therapeutics for the treatment of various diseases, including cancer, immunological disorders, and rare genetic diseases.

Inhibrx utilizes a proprietary platform called single-domain antibody (sdAb) technology, which allows for the creation of highly specific and potent antibodies. These sdAbs have the ability to target and bind to specific disease-causing proteins, known as antigens, with high affinity.

The company's sdAb-based therapeutics have the potential to provide significant benefits over traditional antibody therapies, including improved tissue penetration, increased stability, and enhanced safety profiles. Inhibrx is dedicated to advancing these innovative treatments through rigorous preclinical and clinical development.

Inhibrx collaborates with pharmaceutical companies, research institutions, and healthcare organizations to accelerate the development and commercialization of its novel antibody therapeutics. The company is committed to making a meaningful impact on patients' lives by providing new treatment options for a range of debilitating and life-threatening diseases.


   Company Address: 11025 N. Torrey Pines Road La Jolla 92037 CA
   Company Phone Number: 795-4220   Stock Exchange / Ticker: NASDAQ INBX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Inhibrx Inc

Inhibrx Inc Faces Profitability Challenges Despite Revenue Surge in Q4 2023

Inhibrx Inc, a biotechnology and pharmaceuticals company, has announced impressive financial results for the fourth quarter of 2023. Despite the challenging market conditions faced by many companies in the sector, Inhibrx Inc saw a significant improvement in revenue, with a 496.35% year-on-year increase to $1.63 million. However, the company also reported an increased shortfall per share at $-1.50.
Compared to the previous reporting period, the shortfall per share advanced from $-1.10, while revenue more than doubled by 1273.109% from $0.12 million. Inhibrx Inc's net shortfall for the fourth quarter of 2023 was $-93.604 million, which is larger than the $-40.915 million reported in the same period a year ago.

Inhibrx Inc

Headline: Diminishing Returns Expand at Biotechnology & Pharmaceuticals Company Throughout July-September 2023 Fiscal Period, Inhibrx Inc. Takes More Sophisticated Approach

Inhibrx Inc, a biopharmaceutical company, has recently disclosed its third quarter financial report for 2023, which showed a significant decline in revenue. The company's revenue decreased by -57.194% to $0.12 million compared to the same quarter last year. Additionally, the shortfall per share increased to $-1.10 from the previous year's corresponding quarter.
In comparison to the previous quarter, where the company reported a shortfall per share of $-1.08, there has been a slight improvement with revenue doubling by 296.667% to $0.03 million.

Inhibrx Inc

Inhibrx Inc Reports Soaring Demand and Growth Potential Amidst Major Financial Setback



Inhibrx Inc, a pharmaceutical company, recently released its financial results for the interval ending June 30, 2023. The report indicates a significant decline in revenue and an expansion of net loss per share compared to the previous reporting season. However, amidst the challenging financial figures, there are also signs of rising demand and potential for growth.
Financial Results:
1. Declining Revenue:
Inhibrx Inc experienced a sharp decline in revenue, with a decrease of -95.781% to $0.03 million. This is a significant drop compared to the previous reporting season, where revenue surged by 76.471% to $0.02 million.

Inhibrx Inc

Inhibrx Inc: Battling Adversity Throughout the First Quarter of 2023

Inhibrx Inc is a biotechnology company that specializes in developing novel biologic medicines for the treatment of serious and life-threatening diseases. The company focuses on developing antibodies that target specific proteins involved in the progression of diseases, with the goal of blocking their activity and stopping the disease from progressing.
Despite its impressive research and development efforts, Inhibrx has had a difficult start to 2023. In a recent announcement, the company reported disastrous financial results, with revenue falling by -98.17% to just $0.02 million for the period of January to March 31 2023. This is a significant decline compared to the corresponding reporting period a year before, where revenue had already tumbled by -93.796% from $0.27 million.






 

Inhibrx Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Inhibrx Inc does not provide revenue guidance.

Earnings Outlook
Inhibrx Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com